A new study published in the journal Neurobiology of Sleep and Circadian Rhythms provides evidence that exposure to blue ...
Kite, a Gilead Company , presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large ...